INVO Fertility Inc. (IVF) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Capital intensity & 0% operating margin leave 16 pts on the table
While IVF currently carries a cautious 43/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.34) and Max Pain ($0.57) forces dealer call-delta covering toward $102.98.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
INVO Fertility Inc. (IVF) dropped -3.60% to $0.54, trading at 2% of its 52-week range ($1.59 – $98.08). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SARASOTA, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the establishment, acquisition and operation of fertility clinics and related businesses and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IVF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IVF. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, INVO Fertility Inc. (IVF) ranks #566 by composite RQD confidence (43/100, grade D-) and #988 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, IVF leads on earnings valuation at N/A trailing P/E, while IVF leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. ICCM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with IVF at 43/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IVF
ACTIVE
INVO Fertility Inc. | D- | 43/100 | — | 96.0% | -35.0% | -3.60% | $2.5M | Benchmark Subject |
| BJDX Bluejay Diagnostics Inc. | D | 45/100 | — | — | -35.0% | -5.08% | $2.4M | /bjdx-vs-ivf → |
| NXGL NexGel Inc | E | 32/100 | — | 39.5% | -35.0% | -3.72% | $1.9M | /nxgl-vs-ivf → |
| ICCM IceCure Medical Ltd. | D | 46/100 | — | 36.3% | -35.0% | -2.13% | $3.3M | /iccm-vs-ivf → |
| CODX Co-Diagnostics Inc. | D- | 37/100 | — | 64.3% | -35.0% | -10.49% | $3.5M | /codx-vs-ivf → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), INVO Fertility Inc. (IVF) reported GAAP revenue of $6.8M (+4.3% vs. FY2024 revenue of $6.6M , and +126.5% cumulative change since FY2023) , GAAP net income of $23.3M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (-123.5% YoY). On the balance sheet, IVF closed FY2025 with $20.2M in total assets against $744.7K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.8M | $23.3M | -$7.0M | -$7.1M | $20.2M | $744.7K |
| FY2024 (FY) | 2024-12-31 | $6.6M | $9.1M | -$3.0M | -$3.2M | $46.1M | $1.1M |
| FY2023 (FY) | 2023-12-31 | $3.0M | $8.0M | -$4.8M | -$4.8M | — | — |
As of 2026-11-01, INVO Fertility Inc. (NASDAQ: IVF) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $0.54 (-3.60% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, IVF ranks #566 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), IVF carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, BJDX (Bluejay Diagnostics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M) and NXGL (NexGel Inc) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, IVF leads on earnings multiple (N/A) while IVF leads on capital efficiency (-35.0% ROIC).
Per IVF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417926), INVO Fertility Inc. generated $6.8M in revenue (+4.3% YoY), $23.3M in net income, and -$7.1M in free cash flow against $20.2M in total assets and $744.7K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IVF last traded at $0.54 (-3.60% on volume of 119,392 shares), positioning the stock -83.83% below its 50-day simple moving average ($3.34) and -94.12% below its 200-day simple moving average ($9.18). Across its 52-week range of $1.59 to $98.08, IVF sits at the 0.0% percentile with a 14-day RSI of 26.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).
Why IVF Stock dropped -3.60% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.